Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
February 07, 2022 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Provides Business Update and Outlook for 2022
January 13, 2022 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
December 20, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
December 09, 2021 07:00 ET
|
Achilles Therapeutics PLC
-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with...
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
November 12, 2021 07:00 ET
|
Achilles Therapeutics PLC
LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 08:00 ET
|
Achilles Therapeutics PLC
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
October 22, 2021 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
October 12, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Present at Upcoming Scientific Congresses
October 01, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will...